

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Airdoc Technology Co., Ltd.
北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2251)

**SUPPLEMENTAL ANNOUNCEMENT IN RELATION
TO THE ANNUAL REPORT OF THE COMPANY
FOR THE YEAR ENDED DECEMBER 31, 2023**

INTRODUCTION

Reference is made to the 2023 annual report of Beijing Airdoc Technology Co., Ltd. (the “**Company**”) for the year ended December 31, 2023 (the “**2023 Annual Report**”) published on the websites of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Company on April 25, 2024. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the 2023 Annual Report.

In addition to the information provided in the 2023 Annual Report, the Company would like to provide the Shareholders and potential investors of the Company with additional information pursuant to paragraphs 32(4) and 32(4A) of Appendix D2 to the Listing Rules under the paragraph headed “Significant Investments, Material Acquisitions and Disposals” of the 2023 Annual Report.

As of December 31, 2023, the Group held certain investment and wealth management products, which carries a value of 5% or more of the Group's total assets, the details of which are set out as follows:

Name of investment/ wealth management products	Investment cost	Fair value as of December 31, 2023 (RMB'000)	Unrealized gain for the Reporting Period ⁽³⁾ (RMB'000)	Size relative to the total assets of the Group as of December 31, 2023 (%)	Percentage of interests held
New China Innovation Fund ("New China Product") ⁽¹⁾	US\$15,000,000	108,437	2,731	6.44	100.00%
IndexCap Med&Tech I L.P. ("IndexCap") ⁽²⁾	US\$14,500,000	103,058	5,000	6.12	24.81%

Notes:

- (1) Representing the wealth management product subscribed for by the Company from New China Innovation Fund SPC on January 25, 2022. The New China Product primarily invests in fixed income securities or instruments. As of the date of this announcement, the entire principal amount subscribed to New China Innovation Fund has been fully redeemed.
- (2) Representing the limited partnership interest in IndexCap Med&Tech I L.P. subscribed for by a wholly-owned subsidiary of the Company on January 24, 2023. IndexCap is a British Virgin Islands limited partnership with a focus on investing in overseas companies in medicine and health, science and technology industries which its general partner deems appropriate. For further details of the transaction, please refer to the announcements of the Company dated January 24, 2023 and February 6, 2023, respectively.
- (3) The relevant investment and wealth management products did not record any realized gains or receive any dividend for the Reporting Period.

The Group has adopted a prudent investment strategy and would closely monitor the market changes and adjust its investment portfolio as and when necessary. The Group intends to hold these investments as needed aiming to generating a stable income.

Save as disclosed above, the Group did not have other significant investments for the Reporting Period. Save as disclosed in this announcement, all other information in the 2023 Annual Report remains unchanged.

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, October 16, 2024

As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Ms. WANG Lin, Dr. HE Chao and Mr. QIN Yong as executive Directors; and Dr. WU Yangfeng and Dr. HUANG Yanlin as independent non-executive Directors.